

22 Jan 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to *Scrip* on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 20 January 2023, including: the best of J.P. Morgan; [Novartis AG](#) on its US-first commercial plan; [Chugai Pharmaceutical Co., Ltd.](#) CEO talks to us on the [Roche Holding AG](#) alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the outlook for biopharma funding.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[The Best Of J.P. Morgan – Valuations, Deals And The IRA](#)" - Scrip, 16 Jan, 2023.)

(Also see "[Novartis On Its 'US First' Commercial Plan](#)" - Scrip, 17 Jan, 2023.)

(Also see "[Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda](#)" - Scrip, 16 Jan, 2023.)

(Also see "[Scrip Asks... What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement](#)" - Scrip, 18 Jan, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[*Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue*](#)" - Scrip, 16 Jan, 2023.)

[Click here to explore this interactive content online](#) ✨